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Abstract
Background & Aims: Some individuals with hepatitis C virus infection treated with
direct-acting antivirals require ribavirin to maximize sustained virological response rates.
We describe the clinical management of ribavirin dosing in hepatitis C virus-infected
patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Methods: We performed a post hoc analysis of patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 or 24 weeks in six phase 3 trials.
Multivariate stepwise logistic regression models assessed predictors associated with
ribavirin dose adjustments and with developing anaemia.
Results: Of 1548 patients, 100 (6.5%) modified ribavirin dose due to haemoglobin
declines, of which 99% achieved sustained virological response at 12 weeks post-
treatment. Median time to first ribavirin dose reduction was 37 days. Low baseline
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haemoglobin was significantly associated with an increased risk of requiring ribavirin
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dose modification (odds ratio: 0.618 [0.518, 0.738]; P < .001) and developing anaemia
(odds ratio: 0.379 [0.243, 0.593]; P < .001).
Conclusions: Ribavirin dose reductions were infrequent, occurred early in treatment,
and did not impact sustained virological response at 12 weeks post-treatment. Patients
with low baseline haemoglobin should be monitored for on-treatment anaemia.

anaemia, dasabuvir, ombitasvir, paritaprevir, ribavirin
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the risk of post-treatment viral relapse and increase rates of sustained virological response (SVR) in patients with hepatitis C virus

In combination with standard interferon and pegylated interferon

based
(HCV) infection.1,2 Despite improving the efficacy of IFN-

(pegIFN), ribavirin (RBV) has been shown to significantly decrease

therapy, RBV is associated with haemolytic anaemia,3,4 a phenom-

Abbreviations: AASLD, American Association for the Study of Liver Diseases; BMI, body
mass index; CrCl, creatinine clearance; DAA, direct-acting antivirals; DSV, dasabuvir; GT,
genotype; HCV, hepatitis C virus; LLOQ, lower limit of quantification; OBV, ombitasvir;
pegIFN, pegylated interferon; PTV, paritaprevir; RBV, ribavirin; r, ritonavir; SD, standard
deviation; SVR12, sustained virological response 12 weeks post-treatment; SVR, sustained virological response.
ClinicalTrials.gov.
numbers:
NCT01716585,
NCT01767116, NCT01833533, NCT01704755.

NCT01715415,

NCT01674725,

enon driven by accumulation of RBV in erythrocytes and oxidative damage within the red blood cells.5 RBV-associated decline in
haemoglobin levels is dose-dependent and can be exacerbated by
the suppressive effects of interferon on bone marrow,6 which suppresses compensatory reticulocytosis.7
In the current era of all-oral, IFN-free, direct-acting antivirals
(DAAs) for the treatment of HCV, clinical trial data have shown that
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the addition of RBV to DAA treatment regimens can result in higher
SVR rates by reducing post-treatment viral relapse and limiting selection of HCV resistance-associated variants among some difficult-
to-cure individuals.8-10
Six phase 3 trials evaluated the all-oral DAA regimen of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease
inhibitor identified by AbbVie and Enanta, and dosed with ritonavir,
PTV/r) and dasabuvir (DSV, a non-nucleoside NS5B RNA polymerase
inhibitor) with or without RBV in HCV genotype (GT)1-infected patients that were either treatment naive or pegIFN experienced, with
or without compensated cirrhosis.

8,11-14

Overall, the frequency and

clinical severity of anaemia were low across the six trials; 6.5% of
subjects had a decrease in haemoglobin levels to <10 g/dL during
treatment with OBV/PTV/r + DSV + RBV, and <1% had a haemoglobin decrease to <8 g/dL.

8,11-14

Anaemia-
related adverse events can be effectively managed
through adjustments in RBV dose. However, optimal clinical management of anaemia requires an understanding of (1) when clinically
significant declines in haemoglobin levels are likely to occur, (2) the

Key points
• Among 1548 patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 or
24 weeks in six phase 3 trials, ribavirin dose reductions
due to haemoglobin declines were infrequent, occurring
in 100 (6.5%) patients
• Ribavirin dose reductions with ombitasvir/paritaprevir/
ritonavir and dasabuvir with ribavirin occurred early in
treatment and did not impact sustained virological response at 12 weeks post-treatment
• Low baseline haemoglobin was significantly associated
with an increased risk of requiring ribavirin dose modification and developing anaemia
• Patients with low baseline haemoglobin should be monitored for on-treatment anaemia with ombitasvir/paritaprevir/ritonavir

and

dasabuvir

with

ribavirin

treatment

characteristics of patients that are likely to require RBV dose reductions and (3) the impact of RBV dose reductions on treatment
outcomes. This post hoc pooled analysis describes the clinical management of RBV dosing in GT1-infected patients receiving OBV/

modification as the dependent variable, and among the 100 patients

PTV/r + DSV + RBV in six phase 3 trials.

with a RBV dose modification, anaemia (haemoglobin <10 g/dL) was
modelled as the dependent variable. Independent variables in both
regression models included age, sex, race, ethnicity, prior pegIFN/
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RBV treatment experience, baseline cirrhosis status, and baseline
values for body mass index (BMI), haemoglobin, CrCl, albumin and

Patients in the phase 3 SAPPHIRE-I and -II, PEARL-II, -III and -IV,

platelet count.

and TURQUOISE-II studies received OBV/PTV/r (25/150/100 mg

All patients in the studies provided written informed consent

once daily) and DSV (250 mg twice daily) for 12 weeks (non-cirrhotic

before any study-specific procedures were carried out. The studies

patients), or for either 12 or 24 weeks (cirrhotic patients). Where ad-

were conducted in accordance with the International Conference on

ministered, RBV was dosed according to body weight with a total

Harmonisation guidelines, applicable regulations and the principles

daily dose of 1000 mg (<75 kg) or 1200 mg (≥75 kg). The design,

of the Declaration of Helsinki. The study protocols were approved

patient characteristics, and overall efficacy and safety outcomes of

by each of the independent ethics committees (IECs) or institutional

these studies have been described previously.8,11-14

review boards (IRBs) at each of the participating study sites (a list of

RBV dose modifications were protocol-specified for (1) patients

IECs/IRBs can be found in Table S1).

without cardiac disease with a haemoglobin decline to <10 g/dL,
or a haemoglobin decline ≥4 g/dL in two consecutive visits; (2) patients with cardiac disease with a haemoglobin decline to <12 g/
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dL, or a haemoglobin decline ≥2 g/dL during 4 weeks of treatment
and (3) any patient with a confirmed calculated creatinine clearance

In the six phase 3 studies, the overall rate of patients requiring a

(CrCl) <50 mL/min. RBV dose was reduced according to the local

RBV dose modification was low. Of 1548 patients receiving RBV,

Prescribing Information for RBV.

only 100 (6.5%) reduced the RBV dose due to haemoglobin de-

The percentage of patients with first and with second RBV dose

clines. A total of 715 (46.2%) of these patients received an OBV/

modifications, and the mean and median time to first and secondary

PTV/r + DSV + RBV regimen that is recommended by the current

modifications were calculated. Mean haemoglobin concentrations

(2016) guidelines of the American Association for the Study of Liver

over time were plotted for patients with and without RBV dose

Diseases (AASLD).15 Five patients received erythropoietin (four pa-

modifications.

tients in TURQUOISE-II and one patient in SAPPHIRE-I); none re-

Stepwise logistic regression models (α = 0.10 to enter and to re-

ceived a blood transfusion.11,16

main in the model) assessed predictors associated with RBV dose

At first dose adjustment, the majority of patients (56/100; 56%)

modification and predictors associated with developing anaemia.

were managed with a reduction in RBV dose to 600 mg, and only

Among all patients, stepwise logistic regression modelled RBV dose

10 patients (10/100; 10%) were reduced to 400 mg or lower. The

|
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TA B L E 1 Patient characteristics
associated with increased risk of RBV
dose modification and anaemiaa

1573

Odds ratio

95% CI

P

Baseline haemoglobin level (continuous, g/dL)

0.618

0.518, 0.738

<.001

Baseline CrCl (continuous, mL/s)

0.261

0.123, 0.554

<.001

Increased risk of RBV dose modification

Age (continuous, years)

1.06

1.02, 1.09

<.001

Baseline BMI (continuous, kg/m2)

1.08

1.02, 1.15

.013

Increased risk of anaemia (haemoglobin <10 g/dL) among patients with RBV dose modifications
Baseline haemoglobin level (continuous, g/dL)

0.379

0.243, 0.593

<.001

a

Independent baseline variables that were considered in the stepwise multivariate logistic regression models were age (years), prior pegIFN/RBV experience (yes, no), sex (male, female), race (black,
Asian, white), ethnicity (Hispanic/Latino, other), baseline cirrhosis status (yes, no), and baseline values for BMI (kg/m2), haemoglobin (g/dL), CrCl (mL/s), platelet count (109/L), albumin (g/L).
BMI, body mass index; CrCl, creatinine clearance; RBV, ribavirin.

majority (65%) of RBV dose reductions occurred within the first
6 weeks of treatment, and the median time to first dose reduction
was 37 days (95% CI 36.0, 44.0; Table S2).
Of the 100 patients that modified the RBV dose, 20 required a
second RBV dose reduction. The majority (14/20; 70%) of secondary
dose adjustments occurred within 8 weeks of starting treatment, on
median day 48 (Table S2). Three (15%) of the 20 patients with at least
two reductions in RBV dose had an increase in RBV dose before the
second RBV dose reduction.
Logistic regression analyses demonstrated that low baseline
haemoglobin level (P < .001), low CrCl rate (P < .001), older age
(P < .001) and higher baseline BMI (P = .013) were associated with a
significantly increased likelihood of requiring a RBV dose modification (Table 1). Differences between these characteristics in patients
with and without RBV dose modifications are presented in Table S2.
In patients with RBV dose reductions, mean haemoglobin declines
were observed within 4 weeks of receiving OBV/PTV/r + DSV + RBV,
after which haemoglobin levels plateaued until the end of treatment
(Figure 1). The mean (±SD) maximum decline in haemoglobin level
was −4.1 ± 1.26 g/dL, compared with −2.7 ± 1.19 g/dL in patients
without RBV dose reductions. Laboratory-confirmed anaemia (haemoglobin <10 g/dL) was observed in 63 of the 100 patients that reduced the RBV dose, and haemoglobin levels declined to <8 g/dL in
four patients. Mean haemoglobin levels returned to near baseline
values by post-treatment week 4 (Figure 1). After RBV dose reduction, recovery of haemoglobin levels during treatment led to an increase in RBV dose in 16 patients (16/100; 16%), as per the study
protocols.
Regression analysis among the 100 patients with RBV modifications identified low baseline haemoglobin (P < .001) as the only
factor significantly associated with developing anaemia (Table 1).
Ribavirin (RBV) dose reductions, including secondary reductions,
did not impact the ability of patients to achieve a sustained virologi-

F I G U R E 1 Mean (±SE) haemoglobin level declines in
patients with or without a ribavirin dose reduction following
OBV/PTV/r + DSV + RBV treatment for 12 weeks (A) or 24 weeks
(B). The mean plot is shown across time for haemoglobin levels in
patients that received ombitasvir/paritaprevir/r and dasabuvir plus
ribavirin in six phase 3 trials

cal response 12 weeks post-treatment (SVR12) in the phase 3 trials.

IL28B non-CC genotype and HCV GT1a infection without cirrhosis

The SVR12 rate among patients that required a reduction in RBV

did not achieve SVR12. Furthermore, reducing the RBV dose prior

dose was 99% (99/100); only one 64-year-old white male with an

to achieve HCV RNA below the lower limit of quantification (LLOQ;

1574
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25 IU/mL) did not affect response rates. All seven patients that re-

should not be used in patients with Child-Pugh B/C cirrhosis due to

quired a dose reduction before HCV RNA <LLOQ achieved SVR12.

an increased risk of hepatotoxicity. 25-27

The one patient who did not achieve SVR12 had HCV RNA <LLOQ at
Study Day 15, prior to reduce RBV dose at Study Day 29.

In summary, although haemoglobin decreases were more common with OBV/PTV/r + DSV + RBV than without the use of RBV
(haemoglobin <10 g/dL did not occur in any patients receiving the
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RBV-free regimen across the six trials), significant anaemia was uncommon and was managed with RBV dose reductions alone in most
patients, without any negative impact on SVR12.

Across six phase 3 studies of OBV/PTV/r + DSV + RBV, RBV dose reductions were required in only 6.5% of patients, compared with approximately 20% of patients receiving pegIFN/RBV therapy in past

AC K N OW L E D G E M E N T S

studies.1,2 Head-to-head studies have recently reported RBV dose

Medical writing support was provided by Elizabeth Cottle of

reductions to be lower in patients receiving OBV/PTV/r + DSV + RBV

Medical Expressions, funded by AbbVie. AbbVie provided fund-

compared with those receiving the first-generation protease inhibi-

ing for this study and participated in design, research, data collec-

tor, telaprevir, in combination with pegIFN/RBV.17

tion, interpretation of data, writing, reviewing and approving of

The majority of RBV dose modifications occurred early in the

the publication.

course of treatment, and successfully halted haemoglobin declines
with only 20% of patients requiring further RBV dose decreases.
The majority of patients were managed with a reduction in RBV
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dose to 600 mg. Moreover, reducing RBV dose prior to achieve HCV
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RNA below the LLOQ had no negative impact on achieving SVR12.
Previous studies evaluating pegIFN/RBV therapy also concluded
that mild to moderate RBV dose reductions do not adversely affect
SVR rates.18,19
In the present analysis, low baseline haemoglobin levels and
low baseline CrCl rates, as well as older age, were identified as predictive factors associated with RBV dose modifications, and these
observations are in keeping with previously reported predictors
of anaemia. 20,21 Higher BMI was identified as a predictor in the
presence of the other predictors although with a low odds ratio
(OR: 1.08; P = .013). There was no significant difference in BMI
between patients with and without RBV dose reductions (P = .396;
Table S3).
The majority (63%) of patients that received a RBV dose modification had declines in haemoglobin to <10 g/dL (Grade 2 anaemia);
only 4% had declines in haemoglobin to <8 g/dL (Grade 3 anaemia).
Across the phase 3 studies, the highest rates of anaemia occurred
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in patients with compensated cirrhosis (TURQUOISE-II),8,11-14 a pa-
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tient population that typically has higher rates of HCV-treatment-
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related adverse events. 22 In the recent TURQUOISE-III study, OBV/
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PTV/r + DSV achieved 100% SVR12 in GT1b-infected patients with
compensated cirrhosis, demonstrating that RBV is not required in
these patients. 23
Using multivariate logistic regression, the only significant factor
associated with anaemia among subjects with RBV dose modifications was lower baseline haemoglobin levels. Therefore, our data
suggest that patients with low baseline haemoglobin levels should
be monitored most carefully for RBV-associated declines in haemoglobin and managed through RBV dose reductions. The same principles also apply to patients with decompensated cirrhosis for whom
current guidelines recommend the use of ribavirin, either weight-
based or low initial dose.15,24 However, it is important to note that,
like all protease-
inhibitor-
containing regimens, OBV/PTV/r + DSV
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